A month has gone by since the last earnings report for Syneos Health (SYNH). Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Syneos Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Syneos Health Q4 Earnings and Revenues Top Estimates
Syneos Health reported fourth-quarter 2019 adjusted earnings per share of $1.03, which beat the Zacks Consensus Estimate by 1.9%. The metric also improved 8.4% from the year-ago figure.
GAAP earnings per share were 86 cents, marking an improvement of 9.5% from the year-ago number.
For 2019, adjusted earnings per share were $3.23, up 12.5% from the year-ago period. The bottom line beat the Zacks Consensus Estimate by 0.6%.
Revenues in Detail
Service revenues in the quarter totaled $1.21 billion. The top line rose 6.1% year over year, beating the Zacks Consensus Estimate by 1.7%.
For 2019, revenues totaled $4.67 billion, up 6.4% year over year. The top line surpassed the Zacks Consensus Estimate by 0.2%.
The Clinical Solutions segment recorded service revenues of $899.3 million in the fourth quarter, up 9.5% year over year (adjusted revenues were up 9.7% at CER). The upside resulted from net new business growth. However, an adverse impact of foreign currency fluctuation offset revenue growth.
Commercial Solutions revenues were $313.7 million in the reported quarter, down 3.3% year over year (adjusted revenues moved down 3.4% at CER). The decline was caused by project cancellations and delays in 2019, and a reduction in medication adherence revenues.
Direct costs (excluding depreciation and amortization) rose 6.2% to $927.9 million in the quarter. Gross margin contracted 22 basis points (bps) to 23.5%.
Selling, general and administrative expenses rose 2.3% year over year to $112.4 million.
However, adjusted operating margin (excluding depreciation, amortization, transaction and integration-related, and restructuring and other expenses) expanded 11 bps from the year-ago quarter to 14.2%.
Syneos Health exited 2019 with cash and cash equivalents, and restricted cash of $163.7 million compared with $155.9 million at the end of 2018.
Cumulative cash flow from operating activities at the end of 2019, was $318.5 million compared with $303.4 million a year ago.
For 2020, the company reaffirmed the service revenue guidance at $4.88-$5 billion. The Zacks Consensus Estimate for the same is pegged at $4.94 billion.
For 2020, Syneos Health reaffirmed the adjusted earnings per share view at $3.58-$3.78. The Zacks Consensus Estimate for the same is pegged at $3.66.
How Have Estimates Been Moving Since Then?
Estimates review followed a downward path over the past two months. The consensus estimate has shifted -25.71% due to these changes.
Currently, Syneos Health has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Syneos Health has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Syneos Health, Inc. (SYNH) : Free Stock Analysis Report
To read this article on Zacks.com click here.